124P Durvalumab in Advanced, Pre-Treated Microsatellite Instability-High Solid Tumors: Results of a Tumor-Agnostic DRUP Trial Cohort

PD-1 inhibitors have proven effective against mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) tumors; however, the efficacy of PD-L1 inhibitors, such as durvalumab, remains to be established in these tumors. In the Drug Rediscovery Protocol (DRUP) patients (pts) are treated with drugs outside their labeled indication, based on a specific tumor molecular profile in multiple parallel cohorts (NCT02925234). Here, we report the results of the tumor-agnostic cohort ‘’durvalumab for dMMR/MSI-H solid tumors’’.